Cullinan Therapeutics Inc
CGEM
Market Cap$444.97M
Close$
$1.50
80.1% downside
Current Fair Value
80.1% downsideOvervalued by 80.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $444.97 Million |
|---|---|
| Enterprise Value | $364.12 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.11 |
| Beta | -0.07 |
| Outstanding Shares | 58,580,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.64 |
|---|---|
| PEG | -75.09 |
| Price to Sales | - |
| Price to Book Ratio | 0.75 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.94 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Cullinan Oncology Inc
24 employeesCullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build a pi...